The biggest obstacle for med-tech giant Medtronic (MDT)
today is not its competition nor the still-sleepy markets for medical
procedures. Instead, the biggest problem Medtronic has is a
market/investor base that seems unwilling to accept the company for what
it is. Medtronic came in shy of the more robust growth expectations
this quarter, but even modest long-term growth projections suggest these
shares are undervalued today.
Please click below to continue:
Growth Needs Resuscitation, But Medtronic Still Looks Like A Value
No comments:
Post a Comment